Effects of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy and Neoadjuvant Intraperitoneal/Systemic Chemotherapy on Peritoneal Metastases from Gastric Cancer
- 1.1k Downloads
The Peritoneal Cancer Index (PCI) is the most important prognostic factor following comprehensive treatment for peritoneal metastasis (PM) from gastric cancer (GCPM); however, 70 % of patients with GCPM showed a PCI score above the cut-off level at the time of diagnosis. Furthermore, neoadjuvant chemotherapy may reduce the PCI score to lower than the cut-off levels. In this study, the effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemoperfusion (NLHIPEC) and neoadjuvant intraperitoneal/systemic chemotherapy (NIPS) were investigated.
Materials and Methods
In group A, NLHIPEC was performed twice in 53 patients with GCPM, separated by a 1-month rest interval. Changes in the PCI were studied at the time of first and second laparoscopy. In group B, after NLHIPEC, a series of 3-week cycles of NIPS were performed over three courses in 52 patients. A laparotomy for cytoreductive surgery (CRS) was then carried out and the PCI changes were studied.
In group A, the PCI score at the time of the second session (11.8 ± 11.0) was significantly lower than at the time of the first session (14.2 ± 10.7), while in group B, the PCI at the time of laparotomy (9.9 ± 11.3) was significantly lower than at the time of NLHIPEC (14.8 ± 11.4). After NLHIPEC plus NIPS, complete cytoreduction was achieved in 30 (57.6 %) patients.
NLHIPEC and NIPS are effective methods of reducing PCI levels before CRS.
KeywordsGastric Cancer Docetaxel Peritoneal Metastasis Peritoneal Cancer Index Complete Cytoreduction
Conflicts of Interest
Yutaka Yonemura, Haruaki Ishibashi, Masamitu Hirano, Akiyoshi Mizumoto, Kazuyosi Takeshita, Kousuke Noguchi, Nobuyuki Takao, Masumi Ichinose, Yang Liu, and Yan Li declare that there were no potential conflicts of interest.
- 4.Canbay E, Yonemura Y. Management of special issues. In: Canbay E, Yonemura Y, editors. Peritoneal surface malignancies: a curative approach. Springer; 2015. pp. 57–80.Google Scholar
- 7.Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–2377.CrossRefPubMedGoogle Scholar
- 14.de Bree E, Tsiftsis DD. Experimental and pharmacologic studies in intraperitoneal chemotherapy from laboratory bench to bedside. In: Gonzalez-Moleno S editor. Advances in peritoneal surface oncology. Springer; 2007. pp. 53–73.Google Scholar
- 19.Levine EA, Stewart JH, Russel GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204(5):943–53; discussion 953–5.Google Scholar
- 20.Yan TD, Links M, Fransi S, Jacques T, Black D, Saunders V, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy: a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol. 2007;14(8):2270–80.CrossRefPubMedGoogle Scholar